Dynavax reported a decrease in total revenue for the fourth quarter of 2022, with $184.5 million compared to $195.1 million for the fourth quarter of 2021. However, HEPLISAV-B vaccine product revenue increased to $34.9 million from $17.2 million in the same period.
Total revenue for Q4 2022 was $184.5 million, compared to $195.1 million for Q4 2021.
HEPLISAV-B vaccine product revenue for Q4 2022 was $34.9 million, compared to $17.2 million for Q4 2021.
CpG 1018 adjuvant product revenue for Q4 2022 was $147.2 million, compared to $177.4 million for Q4 2021.
GAAP net income was $67.7 million, or $0.53 per share (basic) and $0.45 per share (diluted) in Q4 2022, compared to $99.8 million in Q4 2021.
Dynavax anticipates full-year 2023 revenue and operating expenses to be in the ranges below:
Analyze how earnings announcements historically affect stock price performance